Ex-Lehman Executive Jack Can Enter Treatment Program

Bradley Jack, a former Lehman Brothers Holdings Inc. managing director charged with forging prescriptions, can enter a drug and alcohol treatment program, a Connecticut judge ruled.

Superior Court Judge Maureen D. Dennis today granted Jack’s request, which prosecutors didn’t oppose, to enter the program on the conditions that he attend weekly group sessions and participate in self-help programs, receive outpatient psychiatric counseling and submit urine samples upon request.

Jack, 54, is “someone who would benefit from treatment” as he has “struggled in the past” with addiction and is taking steps to address the issue, his attorney, Robert Golger, said in court. Jack, who was in court today, declined an opportunity to address the judge.

The program allows a case to be suspended if the court finds that a defendant was dependent on drugs or alcohol when the offense occurred, that the program would serve the interests of justice and that treatment can help the defendant, according to the Connecticut Judicial Branch. Charges against Jack will be dismissed if he completes the program.

Jack was first arrested on a charge of second-degree forgery in June 2011, when he allegedly obtained forged prescriptions for Ritalin and the painkiller Oxycontin in Fairfield, Connecticut.

A judge allowed Jack to avoid prosecution in that case, under a diversionary program for first-time offenders, as long as he stayed out of trouble for a year. Jack was arrested again in March on second-degree forgery charges after he allegedly altered a prescription for Vyvanase, an attention-deficit disorder drug, in Westport, Connecticut.

A hearing on Jack’s first case is scheduled for Nov. 16.

“I really don’t want to comment on the matter, but I hope it’s going to be resolved,” Golger said after today’s hearing.

To contact the reporters on this story: John Dillon at Connecticut Superior Court in Norwalk at jdillon@snet.net; Chris Dolmetsch in New York at cdolmetsch@bloomberg.net

To contact the editor responsible for this story: Michael Hytha at mhytha@bloomberg.net